{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:23:35Z","timestamp":1787390615943,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Kidney involvement is frequent in AL amyloidosis and significantly impacts prognosis. Although hematologic response is the recommended marker for monitoring treatment efficacy, organ-specific responses are frequently evaluated in clinical practice. In this context, the significance and optimal timing of kidney-specific response remain poorly defined in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of patients with renal AL amyloidosis treated with or without anti-clonal therapy (ACT). Kidney response rates and their timing were analyzed. Patients were stratified by time to kidney response: very early (0\u20136 months), early (6\u201312 months), and late (&amp;gt;12 months). Baseline characteristics, treatments, and outcomes were compared across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-six patients were included; 58 received ACT. Among them, 59% achieved hematologic response and 52% achieved kidney response. Kidney response was associated with improved kidney survival. Median time to hematologic response was 4.58 (1\u20139.38) months, whereas median time to partial and complete kidney response were 9 (6\u201318) and 16.5 (9\u201325) months (P\u00a0=\u00a0.03). Kidney outcomes were similar regardless of response timing. Patients with late kidney response had longer time to hematologic response (9.75 vs. 3 months, P\u00a0=\u00a0.02), longer treatment duration (24.5 vs. 9 months, P\u00a0=\u00a0.02), and received more ACT lines, particularly among those with very early hematologic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Kidney response in AL amyloidosis occurs later than hematologic response but is associated with favorable kidney outcomes. In our study, delayed kidney response was associated with longer treatment duration despite hematologic response. Prospective studies are needed to determine whether treatment decisions based on kidney response alone improve or worsen patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag241","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:46:58Z","timestamp":1785930418000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed kidney response in AL amyloidosis: prevalence and clinical significance"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-9824","authenticated-orcid":false,"given":"Irene","family":"Martin\u00a0Capon","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cifuentes","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E","family":"Ruiz-Cabello","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Cavero","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Au\u00f1\u00f3n","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alonso","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-1071","authenticated-orcid":false,"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-6973","authenticated-orcid":false,"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel M","family":"Sevillano","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026082204363221100_bib1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"2026082204363221100_bib2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.mayocp.2018.08.006","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026082204363221100_bib3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2026082204363221100_bib4","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2026082204363221100_bib5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"2020","author":"Palladini","year":"2020","journal-title":"Hematology"},{"key":"2026082204363221100_bib6","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3390\/jcm13061744","article-title":"Renal AL amyloidosis: updates on diagnosis, staging, and management","volume":"13","author":"Shafqat","year":"2024","journal-title":"J Clin Med"},{"key":"2026082204363221100_bib7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.18632\/oncotarget.28415","article-title":"Systemic AL amyloidosis: current approach and future direction","volume":"14","author":"Bou\u00a0Zerdan","year":"2023","journal-title":"Oncotarget"},{"key":"2026082204363221100_bib8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3324\/haematol.2012.079210","article-title":"A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?","volume":"98","author":"Leung","year":"2013","journal-title":"Haematologica"},{"key":"2026082204363221100_bib9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clml.2017.06.004","article-title":"Primary amyloidosis with renal involvement: outcomes in 77 consecutive patients at a single center","volume":"17","author":"Wong","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026082204363221100_bib10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive Review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al\u00a0Hamed","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026082204363221100_bib11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of al amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"key":"2026082204363221100_bib12","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026082204363221100_bib13","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2026082204363221100_bib14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"2026082204363221100_bib15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00277-008-0652-z","article-title":"Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience","volume":"88","author":"Frossard","year":"2009","journal-title":"Ann Hematol"},{"key":"2026082204363221100_bib16","doi-asserted-by":"publisher","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026082204363221100_bib17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s10157-009-0198-y","article-title":"Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation","volume":"13","author":"Yamazaki","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"2026082204363221100_bib18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13506129.2019.1672650","article-title":"The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis","volume":"27","author":"Angel-Korman","year":"2020","journal-title":"Amyloid"},{"key":"2026082204363221100_bib19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5414\/CN107162","article-title":"A patient with persistent renal AL amyloid deposition after clinical remission by HDM\/SCT therapy","volume":"79","author":"Okuyama","year":"2013","journal-title":"Clin Nephrol"},{"key":"2026082204363221100_bib20","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1093\/ndt\/gfg436","article-title":"No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement","volume":"18","author":"Zeier","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2026082204363221100_bib21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-022-02752-4","article-title":"Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag241\/70496521\/sfag241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag241\/70496521\/sfag241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag241\/70496521\/sfag241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:36:38Z","timestamp":1787387798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag241\/8752649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag241","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,31]]},"article-number":"sfag241"}}